PCVX in the 13F filings
Vaxcyte Inc · CUSIP 92243G108
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 12 Feb 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 9 listed it in both
- Shares listed
- 43,516,131
- combined, among listed positions
- Reported value
- $3.6bn
- combined, at the quarter end
Among the 94 comparable managers: 6 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing PCVX in Q4 2024
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 6,210,523 shares now+1,312,302
- Maverick Capital Ltdexisting position · 1,201,898 shares now+225,649
- AllianceBernstein LPexisting position · 1,779,362 shares now+133,448
- Hudson Bay Capital Management LPnew position · 98,739 shares now+98,739
- Woodline Partners LPexisting position · 1,120,922 shares now+16,977
Reductions
- Fidelity (FMR LLC)existing position · 13,091,648 shares now-2,709,019
- T. Rowe Price Associates Incexisting position · 3,966,956 shares now-499,181
- Janus Henderson Group Ltdexisting position · 10,575,363 shares now-346,533
- Point72 Asset Management LPexisting position · 251,055 shares now-108,741
- Wellington Management Group LLPexisting position · 4,444,012 shares now-69,744
New positions and exits
New (1)
Exited (1)
- Farallon Capital Management LLCwas $3.2m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2020 | 2 | $141m | n.a. | n.a. |
| Q3 2020 | 2 | $515m | n.a. | n.a. |
| Q4 2020 | 1 | $108m | n.a. | n.a. |
| Q1 2021 | 1 | $84m | n.a. | n.a. |
| Q2 2021 | 1 | $93m | n.a. | n.a. |
| Q3 2021 | 1 | $104m | n.a. | n.a. |
| Q4 2021 | 2 | $103m | n.a. | n.a. |
| Q1 2022 | 2 | $106m | n.a. | n.a. |
| Q2 2022 | 4 | $107m | n.a. | n.a. |
| Q3 2022 | 5 | $140m | n.a. | n.a. |
| Q4 2022 | 12 | $1.2bn | n.a. | n.a. |
| Q1 2023 | 8 | $978m | n.a. | n.a. |
| Q2 2023 | 8 | $1.6bn | n.a. | n.a. |
| Q3 2023 | 9 | $1.8bn | n.a. | n.a. |
| Q4 2023 | 9 | $2.1bn | 5 | 4 |
| Q1 2024 | 9 | $2.7bn | 8 | 1 |
| Q2 2024 | 10 | $3.1bn | 4 | 6 |
| Q3 2024 | 12 | $5.1bn | 8 | 4 |
| Q4 2024 | 11 | $3.6bn | 6 | 6 |
| Q1 2025 | 6 | $1.8bn | 3 | 3 |
| Q2 2025 | 7 | $969m | 5 | 2 |
| Q3 2025 | 9 | $940m | 5 | 5 |
| Q4 2025 | 9 | $1.8bn | 13 | 18 |
| Q1 2026 | 12 | $2.7bn | 18 | 13 |
| Q2 2026 | 8 | $2.9bn | 13 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PCVX and GILD →PCVX and AMGN →PCVX and ARGX →Choose a stock to compare with PCVX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PCVX, latest filings →Back to the 13F Explorer →